Literature DB >> 12941917

Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection.

A E Zautner1, U Körner, A Henke, C Badorff, M Schmidtke.   

Abstract

Amino acid exchanges in the virus capsid protein VP1 allow the coxsackievirus B3 variant PD (CVB3 PD) to replicate in decay accelerating factor (DAF)-negative and coxsackievirus-adenovirus receptor (CAR)-negative cells. This suggests that molecules other than DAF and CAR are involved in attachment of this CVB3 variant to cell surfaces. The observation that productive infection associated with cytopathic effect occurred in Chinese hamster ovary (CHO-K1) cells, whereas heparinase-treated CHO-K1 cells, glucosaminoglycan-negative pgsA-745, heparan sulfate (HS)-negative pgsD-677, and pgsE-606 cells with significantly reduced N-sulfate expression resist CVB3 PD infection, indicates a critical role of highly sulfated HS. 2-O-sulfate-lacking pgsF-17 cells represented the cell line with minimum HS modifications susceptible for CVB3 PD. Inhibition of virus replication in CHO-K1 cells by polycationic compounds, pentosan polysulfate, lung heparin, and several intestinal but not kidney HS supported the hypothesis that CVB3 PD uses specific modified HS for entry. In addition, recombinant human hepatocyte growth factor blocked CVB3 PD infection. However, CAR also mediates CVB3 PD infection, because this CVB3 variant replicates in HS-lacking but CAR-bearing Raji cells, infection could be prevented by pretreatment of cells with CAR antibody, and HS-negative pgsD-677 cells transfected with CAR became susceptible for CVB3 PD. These results demonstrate that the amino acid substitutions in the viral capsid protein VP1 enable CVB3 PD to use specific modified HS as an entry receptor in addition to CAR.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941917      PMCID: PMC224569          DOI: 10.1128/jvi.77.18.10071-10077.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Expression of the adenovirus receptor and its interaction with the fiber knob.

Authors:  R P Tomko; C B Johansson; M Totrov; R Abagyan; J Frisén; L Philipson
Journal:  Exp Cell Res       Date:  2000-02-25       Impact factor: 3.905

Review 2.  Functions of cell surface heparan sulfate proteoglycans.

Authors:  M Bernfield; M Götte; P W Park; O Reizes; M L Fitzgerald; J Lincecum; M Zako
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

3.  The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction.

Authors:  C J Cohen; J T Shieh; R J Pickles; T Okegawa; J T Hsieh; J M Bergelson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

4.  Human coxsackie-adenovirus receptor is colocalized with integrins alpha(v)beta(3) and alpha(v)beta(5) on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy: implications for cardiotropic viral infections.

Authors:  M Noutsias; H Fechner; H de Jonge; X Wang; D Dekkers; A B Houtsmuller; M Pauschinger; J Bergelson; R Warraich; M Yacoub; R Hetzer; J Lamers; H P Schultheiss; W Poller
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

5.  Expression of coxsackievirus and adenovirus receptor in hearts of rats with experimental autoimmune myocarditis.

Authors:  M Ito; M Kodama; M Masuko; M Yamaura; K Fuse; Y Uesugi; S Hirono; Y Okura; K Kato; Y Hotta; T Honda; R Kuwano; Y Aizawa
Journal:  Circ Res       Date:  2000-02-18       Impact factor: 17.367

6.  The coxsackie-adenovirus receptor (CAR) is used by reference strains and clinical isolates representing all six serotypes of coxsackievirus group B and by swine vesicular disease virus.

Authors:  T A Martino; M Petric; H Weingartl; J M Bergelson; M A Opavsky; C D Richardson; J F Modlin; R W Finberg; K C Kain; N Willis; C J Gauntt; P P Liu
Journal:  Virology       Date:  2000-05-25       Impact factor: 3.616

7.  Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1.

Authors:  M Schmidtke; H C Selinka; A Heim; B Jahn; M Tonew; R Kandolf; A Stelzner; R Zell
Journal:  Virology       Date:  2000-09-15       Impact factor: 3.616

8.  Coxsackievirus infection of the pancreas: evaluation of receptor expression, pathogenesis, and immunopathology.

Authors:  I Mena; C Fischer; J R Gebhard; C M Perry; S Harkins; J L Whitton
Journal:  Virology       Date:  2000-06-05       Impact factor: 3.616

9.  Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection.

Authors:  L K Hallak; P L Collins; W Knudson; M E Peeples
Journal:  Virology       Date:  2000-06-05       Impact factor: 3.616

10.  Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions.

Authors:  M C Dechecchi; A Tamanini; A Bonizzato; G Cabrini
Journal:  Virology       Date:  2000-03-15       Impact factor: 3.616

View more
  35 in total

1.  Induction of a broad spectrum of inflammation-related genes by Coxsackievirus B3 requires Interleukin-1 signaling.

Authors:  Fabienne Rehren; Barbara Ritter; Oliver Dittrich-Breiholz; Andreas Henke; Elena Lam; Semra Kati; Michael Kracht; Albert Heim
Journal:  Med Microbiol Immunol       Date:  2012-06-03       Impact factor: 3.402

2.  Variations of coxsackievirus B3 capsid primary structure, ligands, and stability are selected for in a coxsackievirus and adenovirus receptor-limited environment.

Authors:  Steven D Carson; Nora M Chapman; Susan Hafenstein; Steven Tracy
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

3.  Human astrocytic cells support persistent coxsackievirus B3 infection.

Authors:  Xiaowei Zhang; Zhenhua Zheng; Bo Shu; Xijuan Liu; Zhenfeng Zhang; Yan Liu; Bingke Bai; Qinxue Hu; Panyong Mao; Hanzhong Wang
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

4.  Single Neutralizing Monoclonal Antibodies Targeting the VP1 GH Loop of Enterovirus 71 Inhibit both Virus Attachment and Internalization during Viral Entry.

Authors:  Zhiqiang Ku; Xiaohua Ye; Jinping Shi; Xiaoli Wang; Qingwei Liu; Zhong Huang
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

5.  Interaction with coxsackievirus and adenovirus receptor, but not with decay-accelerating factor (DAF), induces A-particle formation in a DAF-binding coxsackievirus B3 isolate.

Authors:  Aaron M Milstone; JenniElizabeth Petrella; Melissa D Sanchez; Mariam Mahmud; J Charles Whitbeck; Jeffrey M Bergelson
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 6.  Peptide antimicrobial agents.

Authors:  Håvard Jenssen; Pamela Hamill; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

7.  Human rhinovirus type 54 infection via heparan sulfate is less efficient and strictly dependent on low endosomal pH.

Authors:  Abdul Ghafoor Khan; Johannes Pichler; Anke Rosemann; Dieter Blaas
Journal:  J Virol       Date:  2007-02-14       Impact factor: 5.103

Review 8.  Multiple roles of the coagulation protease cascade during virus infection.

Authors:  Silvio Antoniak; Nigel Mackman
Journal:  Blood       Date:  2014-03-14       Impact factor: 22.113

9.  The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system.

Authors:  Arnab Basu; Aster Beyene; Keith Meyer; Ranjit Ray
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X.

Authors:  Angela C Bradshaw; Alan L Parker; Margaret R Duffy; Lynda Coughlan; Nico van Rooijen; Veli-Matti Kähäri; Stuart A Nicklin; Andrew H Baker
Journal:  PLoS Pathog       Date:  2010-10-07       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.